InspireMD

NSPR

市值 US$2132萬

- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -

MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of September 2, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C.

InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of 2025.

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago.

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of August 3, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted under the InspireMD's 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).

Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime

NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.